Corcept wins patent appeal, discloses DOJ subpoena on Korlym sales, extends tender offer to Dec 15

CORCEPT THERAPEUTICS INC

Federal Circuit affirmed PTAB decision upholding validity of '214 patent (expires 2037) against Teva challenge.
Received HIPAA subpoena from NJ USAO regarding Korlym sales and HCP payments; investigating potential criminal/civil violations; Corcept not a defendant.
Extended tender offer expiration to Dec 15, 2021; 8,282,336 shares tendered to date; condition of at least 3M shares tendered.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.